AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
AtriCure Inc. (ATRC) PT Raised to $57 at BTIG
February 13, 2025 5:21 AM ESTBTIG analyst Marie Thibault raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $57.00 (from $53.00) while maintaining a Buy rating.
The analyst comments "AtriCure announced Q4 revenue of $124.3M (+16.6% y/y rep, +16.7% y/y cc), in line with the preliminary announcement last month. This result came in above the implied Q4 guidance range of $118M-$121M, beating consensus and our forecast of $119.8M at the time of the pre-announcement. U.S.... More



